Stool tests
ProcedureNon-invasive, stool-based tests for colorectal cancer screening.
Other names: Stool-based Fecal Immunochemical Testing (FIT) test and Stool-based DNA test (Cologuard) test.
NCT Number: NCT05362344
This multi-center study will compare multi-target DNA and quantitative FIT stool-based testing to colonoscopy in individuals with Cystic Fibrosis (CF) undergoing colon cancer screening with colonoscopy. The primary endpoint is detection of any adenomas, including advanced adenomas and colorectal cancer (CRC).
This study is active but is not currently recruiting participants.
18 year–75 year
All sexes
Observational
University of California, Los Angeles, Los Angeles, California, United States
NICE-CF is a cross-sectional, multi-center study comparing stool-based testing (multi-target DNA test and quantitative FIT test) to standard of care colonoscopy for colorectal cancer (CRC) screening in people with CF. The study includes an enrollment visit, two stool samples completed at home, a clinical screening colonoscopy, and three participant surveys which will be completed at enrollment or remotely.
The total duration of participant participation will be 3-12 months, depending on the timing of the completion of the stool samples and the participant's colonoscopy. The targeted participant timeline is 3 months from enrollment to the completion of a clinical screening colonoscopy. To allow for varying site-specific clinical colonoscopy scheduling delays and COVID delays in scheduling, the duration of time between submitting stool samples and screening colonoscopy may extend up to 12 months for inclusion of data in the study. However, participating sites must notify the DCC to obtain preapproval for greater than 3 months duration between stool-based testing and colonoscopy.
CF patients who are eligible for CRC screening will either be enrolled during an in-person CF clinic visit or via phone/video if clinic visits are taking place remotely. Participants will be asked to perform stool sample collection at home, and then complete their colonoscopy within three to twelve months of submission of the stool sample.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Non-invasive, stool-based tests for colorectal cancer screening.
Other names: Stool-based Fecal Immunochemical Testing (FIT) test and Stool-based DNA test (Cologuard) test.
Time frame: 3-12 months
Negative predictive value (NPV) and sensitivity for detection of any adenomas, advanced adenomas, and CRC in stool-based testing.
Time frame: 3-12 months
Specificity and positive predictive value (PPV) of stool-based testing for any adenomas, advanced adenomas, and CRC
Time frame: 3-12 months
Overall prevalence of any adenomas detected by screening and by colonoscopy
Time frame: 3-12 months
Overall prevalence of advanced adenomas detected by screening and by colonoscopy
Time frame: 3-12 months
Overall prevalence of CRC detected by screening and by colonoscopy
Time frame: 3-12 months
Overall prevalence of sessile serrated lesions detected by screening and by colonoscopy
Time frame: 3-12 months
Proportion of patients who complete stool-based testing
Time frame: 3-12 months
Proportion of study participants who complete colonoscopy and stool-based testing
Time frame: 3-12 months
Comparison of the predictive ability of the two tests
Time frame: 3-12 months
Qualitative surveys on ease of stool sample collection and colonoscopy prep
University of Washington, the Collaborative Health Studies Coordinating Center
Other
A Multi-Center Study of Non-Invasive Colorectal Cancer Evaluation in Cystic Fibrosis (NICE-CF)
Acronym: NICE-CF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01931644
ADD/ADHD, Abnormalities, Multiple
Los Angeles, California, United States
View Trial DetailsNCT05444257
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Birmingham, Alabama, United States
View Trial DetailsNCT05331183
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Innsbruck, Austria
View Trial DetailsNCT03256773
Abnormalities, Multiple, COPD
Birmingham, Alabama, United States
View Trial Details